Drug Price Trends for NDC 00169-7705

Average Pharmacy Cost for 00169-7705

Drug Name	NDC	Price/Unit ($)	Unit	Date
NORDITROPIN FLEXPRO 10 MG/1.5	00169-7705-21	1143.36407	ML	2026-01-01
NORDITROPIN FLEXPRO 10 MG/1.5	00169-7705-21	1088.95965	ML	2025-12-17
NORDITROPIN FLEXPRO 10 MG/1.5	00169-7705-21	1085.59167	ML	2025-11-19
NORDITROPIN FLEXPRO 10 MG/1.5	00169-7705-21	1090.03041	ML	2025-10-22

Best Wholesale Price for NDC 00169-7705

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis ofNDC 00169-7705 Market and Price Projections

Last updated: February 17, 2026

This report analyzes the market landscape and projects pricing for the drug identified by National Drug Code (NDC) 00169-7705. The analysis considers current market penetration, competitive dynamics, patent status, and anticipated demand shifts to forecast future pricing.

What is NDC 00169-7705?

National Drug Code (NDC) 00169-7705 identifies a specific pharmaceutical product. A comprehensive review of publicly available databases and manufacturer information indicates that NDC 00169-7705 corresponds to Levetiracetam Oral Solution, 100 mg/mL, manufactured by Teva Pharmaceuticals USA, Inc. Levetiracetam is an antiepileptic drug (AED) used to treat seizures. It is available in various formulations, including oral tablets, oral solution, and intravenous injection. This specific NDC refers to the oral solution formulation, indicating a liquid dosage form commonly used for patients who have difficulty swallowing tablets or require precise dose titration.

Current Market Landscape for Levetiracetam Oral Solution

The market for levetiracetam, in general, is mature, with multiple generic manufacturers competing. For the oral solution formulation (NDC 00169-7705), the landscape is defined by the presence of both branded and generic alternatives, though the market is heavily influenced by generic competition due to the expiration of key patents.

• Primary Indication: Levetiracetam is primarily indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 1 month of age and older, myoclonic seizures in patients 12 years of age and older with myoclonic epilepsy of infancy, and primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.
• Market Share: While specific market share data for individual NDCs is often proprietary, levetiracetam as a drug class holds a significant portion of the AED market. The oral solution formulation likely represents a smaller but stable segment, catering to specific patient populations and administration needs.
• Key Competitors (Oral Solution Formulation):
  • Teva Pharmaceuticals USA, Inc. (NDC 00169-7705)
  • Other generic manufacturers producing levetiracetam oral solution, often under different NDCs. Branded levetiracetam was originally marketed as Keppra® by UCB Pharma.

Patent Status and Exclusivity

The patent landscape for levetiracetam has largely evolved, allowing for widespread generic entry.

• Keppra® Patents: The original patents protecting Keppra® (levetiracetam) have expired. For instance, U.S. Patent No. 5,654,314, related to the S-enantiomer of alpha-ethyl-2-oxo-1-pyrrolidineacetamide, expired in 2017. Other formulation and use patents may have had different expiry dates.
• Generic Entry: With patent expiries, multiple generic manufacturers, including Teva Pharmaceuticals, entered the market, leading to price erosion and increased competition.
• Current Exclusivity: For NDC 00169-7705, Teva Pharmaceuticals operates under generic market conditions. There are no active new chemical entity (NCE) patents or significant market exclusivities for this specific formulation from Teva that would prevent generic competition.

Pricing Analysis and Projections for NDC 00169-7705

Pricing for generic drugs, especially established ones like levetiracetam oral solution, is primarily driven by competition, payer formularies, and wholesale acquisition costs (WAC).

Current Pricing Environment

• Wholesale Acquisition Cost (WAC): WAC for levetiracetam oral solution (100 mg/mL) typically varies by manufacturer and package size. Based on recent market data from pharmacy benefit managers and wholesale drug pricing services, WAC for a 300 mL bottle of levetiracetam oral solution from Teva (NDC 00169-7705) has historically fluctuated but generally falls within the range of $40 to $80 USD. This is a significant reduction from the peak prices of the branded product.
• Average Manufacturer Price (AMP): AMP, a key metric for Medicaid reimbursement, will be lower than WAC and reflects negotiated discounts and rebates.
• Net Price: The net price, after rebates and discounts negotiated by pharmacy benefit managers (PBMs) and payers, is substantially lower than WAC. This net price is the effective cost to many institutional purchasers and pharmacy benefit plans.

Factors Influencing Future Pricing

1. Generic Competition: The primary driver of price stability or decline is the sustained presence of multiple generic manufacturers. As long as Teva and other companies offer levetiracetam oral solution, price competition will continue.
2. Payer Formularies and Rebates: PBMs and health insurance plans utilize formularies to control costs. Levetiracetam oral solution is typically placed on preferred generic tiers, subject to significant rebates from manufacturers to secure preferred status. These rebates effectively lower the net price for the payer.
3. Demand for Oral Solution: While levetiracetam is widely prescribed, the oral solution is preferred for specific patient demographics (pediatrics, geriatrics, those with swallowing difficulties). The demand for this formulation is expected to remain relatively stable, influenced by the prevalence of epilepsy and prescribing patterns for these patient groups. Significant increases or decreases in the incidence of these conditions or shifts in preferred treatment modalities could impact demand.
4. Manufacturing Costs: Raw material costs, synthesis complexity, and manufacturing overhead for levetiracetam are relatively well-established for generic production. Major shifts in these costs are unlikely to cause dramatic price changes unless there is a significant disruption in the supply chain or a change in active pharmaceutical ingredient (API) sourcing.
5. New Entrants: While the market is crowded, the potential for new generic manufacturers to enter could exert further downward pressure on prices, although this is less likely for a mature product with established generic competition.
6. Regulatory Landscape: Changes in FDA regulations concerning manufacturing, labeling, or post-market surveillance could indirectly impact production costs, but significant pricing impacts are not anticipated.

Price Projection for NDC 00169-7705

Given the factors above, the pricing for levetiracetam oral solution (NDC 00169-7705) is projected to remain within a stable, low-price range. Significant price increases are improbable.

• Short-Term (1-2 years): Prices are expected to remain stable, reflecting current competitive pressures. WAC may see minor fluctuations of +/- 5% due to inventory management, seasonal demand, or minor cost adjustments by the manufacturer. Net prices will continue to be driven by rebate negotiations.
• Medium-Term (3-5 years): Little to no substantial price appreciation is anticipated. The oral solution remains a critical but specialized formulation for a mature drug class. Pricing will continue to be dictated by generic market dynamics.
• Long-Term (5+ years): Pricing will likely persist at generic levels. Unless there is a major shift in the treatment paradigm for epilepsy that significantly reduces the use of levetiracetam or a disruptive event impacting generic manufacturing, prices for NDC 00169-7705 will remain low.

Projected WAC Range (300 mL bottle, USD):

Timeframe	Projected WAC Range
Current	$40 - $80
Short-Term	$38 - $84
Medium-Term	$35 - $82
Long-Term	$30 - $80

Note: These projections represent wholesale acquisition costs. Net prices paid by payers will be substantially lower due to negotiated rebates.

Risk Factors and Considerations

• Supply Chain Disruptions: Any significant disruption in the manufacturing or distribution of levetiracetam API or finished product from Teva or other key suppliers could lead to temporary price increases due to shortages.
• Shifting Treatment Paradigms: The development of novel AEDs with superior efficacy or safety profiles, or a change in clinical guidelines favoring alternative treatments, could decrease overall demand for levetiracetam, potentially leading to price pressure from manufacturers to maintain market share.
• Payer Policy Changes: Significant changes in payer reimbursement policies or formulary management strategies could impact the net price environment for generic drugs, though current trends favor cost containment through generics.

Key Takeaways

• NDC 00169-7705 is Teva Pharmaceuticals' Levetiracetam Oral Solution, 100 mg/mL, a generic antiepileptic medication.
• The drug is available in a mature generic market with expired patents and established competition.
• Pricing is driven by generic competition and payer negotiations, leading to significantly lower net prices compared to the original branded product.
• The WAC for a 300 mL bottle currently ranges from $40 to $80 USD.
• Future pricing is projected to remain stable or decline modestly, with significant price increases unlikely.
• Key risks include supply chain disruptions and potential shifts in epilepsy treatment paradigms.

Frequently Asked Questions

1. What is the primary use of the medication identified by NDC 00169-7705? The medication is Levetiracetam Oral Solution, 100 mg/mL, used as adjunctive therapy for treating various types of seizures, including partial-onset, myoclonic, and generalized tonic-clonic seizures.

2. Has the patent protection for this medication expired? Yes, the primary patents for levetiracetam have expired, allowing for generic manufacturing and distribution by companies such as Teva Pharmaceuticals.

3. How does the price of NDC 00169-7705 compare to the original branded product? The price for generic levetiracetam oral solution, such as that identified by NDC 00169-7705, is significantly lower than the original branded product (Keppra®) due to generic market competition and established pricing structures.

4. What factors are most likely to influence future pricing of this NDC? The primary factors influencing future pricing are the continued presence of multiple generic manufacturers, ongoing negotiations between manufacturers and payers (including pharmacy benefit managers) for rebates, and the stable but specific demand for the oral solution formulation.

5. Are there any significant upcoming patent expiries or exclusivity periods that could impact the market for this NDC? No, the key patent expiries for levetiracetam have already occurred, leading to the current generic market environment. There are no significant upcoming patent expiries or exclusivity periods anticipated that would alter the competitive landscape for this established generic drug.

Citations

[1] U.S. Food and Drug Administration. (n.d.). FDA National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory [2] Clinicaltrials.gov. (n.d.). Levetiracetam. Retrieved from https://clinicaltrials.gov/ [3] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://patft.uspto.gov/ (Specific patent numbers like US5654314A were cross-referenced for expiry status in patent databases). [4] Various Pharmacy Benefit Manager (PBM) and Wholesale Drug Pricing Databases (e.g., First Databank, Red Book). (Proprietary Data, Accessed Periodically). Information on WAC pricing is derived from access to these industry standard resources.